| 3801 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
32 |
| 3802 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
61 |
| 3803 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 3804 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
10 |
| 3805 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
67 |
| 3806 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
57 |
| 3807 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
55 |
| 3808 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
68 |
| 3809 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
61 |
| 3810 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
17 |
| 3811 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
46 |
| 3812 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
34 |
| 3813 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
39 |
| 3814 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
53 |
| 3815 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 3816 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
22 |
| 3817 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
56 |
| 3818 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
42 |
| 3819 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
66 |
| 3820 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
52 |
| 3821 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
13 |
| 3822 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
32 |
| 3823 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
61 |
| 3824 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
72 |
| 3825 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
55 |
| 3826 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
57 |
| 3827 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
62 |
| 3828 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
46 |
| 3829 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
63 |
| 3830 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
65 |
| 3831 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
71 |
| 3832 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
53 |
| 3833 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
57 |
| 3834 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
50 |
| 3835 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
32 |
| 3836 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
71 |
| 3837 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia – Relapse
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
65 |
| 3838 |
Apheresis |
Autologous
|
Amyloidosis
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
63 |
| 3839 |
Apheresis |
Allogeneic
|
Anaplastic Large Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
56 |
| 3840 |
Apheresis |
Autologous
|
Angioimmunoblastic T-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
62 |
| 3841 |
Apheresis |
Allogeneic
|
Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
54 |
| 3842 |
Apheresis |
Allogeneic
|
Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
7 |
| 3843 |
Apheresis |
Allogeneic
|
Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
40 |
| 3844 |
Apheresis |
Allogeneic
|
Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
14 |
| 3845 |
Apheresis |
Allogeneic
|
B-Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
36 |
| 3846 |
Apheresis |
Autologous
|
B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
59 |
| 3847 |
Apheresis |
Autologous
|
B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
33 |
| 3848 |
Apheresis |
Autologous
|
B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
63 |
| 3849 |
Apheresis |
Autologous
|
B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
49 |
| 3850 |
Apheresis |
Allogeneic
|
Chronic Granulomatous Disease
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
28 |
| 3851 |
Apheresis |
Allogeneic
|
Chronic Granulomatous Disease
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
11 |
| 3852 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
62 |
| 3853 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
60 |
| 3854 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 3855 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
52 |
| 3856 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
45 |
| 3857 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
37 |
| 3858 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
62 |
| 3859 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 3860 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
74 |
| 3861 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
31 |
| 3862 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 3863 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
18 |
| 3864 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
68 |
| 3865 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
59 |
| 3866 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
67 |
| 3867 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
62 |
| 3868 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
34 |
| 3869 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
70 |
| 3870 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
71 |
| 3871 |
Apheresis |
Allogeneic
|
Chronic Neutrophilic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
67 |
| 3872 |
Apheresis |
Allogeneic
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
62 |
| 3873 |
Apheresis |
Allogeneic
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
50 |
| 3874 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
68 |
| 3875 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
63 |
| 3876 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma – Relapse
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
65 |
| 3877 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma – Relapse
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
65 |
| 3878 |
Apheresis |
Autologous
|
Diffuse Large B-Cell Lymphoma – Relapse
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
71 |
| 3879 |
Apheresis |
Allogeneic
|
Farber Disease
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
9 |
| 3880 |
Apheresis |
Allogeneic
|
Follicular Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
54 |
| 3881 |
Apheresis |
Autologous
|
Follicular Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
55 |
| 3882 |
Apheresis |
Autologous
|
Follicular Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
64 |
| 3883 |
Apheresis |
Autologous
|
Follicular Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
50 |
| 3884 |
Apheresis |
Autologous
|
Germ Cell Tumor
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
28 |
| 3885 |
Apheresis |
Allogeneic
|
Hemophagocytic Lymphohistiocytosis (Hlh)
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
23 |
| 3886 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
41 |
| 3887 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
40 |
| 3888 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
27 |
| 3889 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
19 |
| 3890 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
26 |
| 3891 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
32 |
| 3892 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
21 |
| 3893 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
37 |
| 3894 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
30 |
| 3895 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
47 |
| 3896 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
36 |
| 3897 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
30 |
| 3898 |
Apheresis |
Allogeneic
|
Hurler Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
2 |
| 3899 |
Apheresis |
Allogeneic
|
Immunodeficiency
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
12 |
| 3900 |
Apheresis |
Allogeneic
|
Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |